STOCKHOLM, April 29, 2022 /PRNewswire/ -- During April,
Calliditas Therapeutics AB (publ) has allotted 830,586 common
shares within the company's warrant program issued in 2018. Thus,
as of April 29, 2022, the number of
shares and votes in the company amounts to 53,172,170.
For further information, please contact:
Mikael Widell, Investor
relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas
Therapeutics AB (publ) is required to disclose pursuant to the
Swedish Financial Instruments Trading Act. The information was
submitted for publication, through the agency of the contact
persons set out above, at 10:00 a.m.
CEST on April 29,
2022.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, TARPEYOTM (budesonide) delayed release
capsules, has been approved by the FDA and is the subject of a
marketing authorization application (MAA) with the European
Medicines Agency (EMA). Additionally, Calliditas is conducting a
pivotal clinical trial with its NOX inhibitor product candidate
setanaxib in primary biliary cholangitis and is initiating a head
and neck cancer Phase 2 trial with setanaxib. Calliditas' common
shares are listed on Nasdaq Stockholm (ticker: CALTX) and its
American Depositary Shares are listed on the Nasdaq Global Select
Market (ticker: CALT).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3556446
The following files are available for download:
|
https://mb.cision.com/Main/16574/3556446/1571537.pdf
|
Number of shares and
votes April 2022
|